Prostate cancer is associated with high mortality among men. The major factors increasing the risk of the disease constitute of old age, heredity, and lifestyle aspects such as smoking and diet rich in red meat. Cancer Digital Rectal Exam (DRE), prostate biopsy, Prostate Specific Antigen (PSA) blood test, bone scan, ultrasound, computed tomography (CT) scan, magnetic resonance imaging (MRI), lymph node biopsy, and ProstaScint monoclonal antibody scan are generally used for the diagnosis of prostate cancer. Laparoscopy, cryosurgery, brachytherapy, and robotic surgery are the common practices surgical techniques while performing minimally invasive surgeries for the treatment of prostate cancer. Factors, such as the increasing prevalence of prostate cancer, increasing product approvals, and increasing investments in research and development, are expected to propel the market growth during the forecast period.
Market Dynamics
Increasing product approvals by regulatory authorities are expected to drive the North America and Europe minimally invasive prostate cancer surgery market growth over the forecast period. For instance, in May 2021, Avenda Health, a health technology company, announced the U.S. Food and Drug Administration (FDA) approval device designation for technology to treat prostate cancer, aiming to improve cancer outcomes through Artificial Intelligence (AI) and minimally invasive technologies. The Avenda Health Focal Therapy System, which is designed to spare healthy tissues and minimize side effects, uses patient-specific information and artificial intelligence (AI) to deliver a precise and personalized treatment, targeting only the tumor. This treatment can be performed in a physician’s office with just local anesthesia, minimizing the patient’s downtime and potentially reducing cost to the healthcare system.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook